| Mutant IDH1 regulates the tumor-associated immune system in gliomas NM Amankulor, Y Kim, S Arora, J Kargl, F Szulzewsky, M Hanke, ... Genes & development 31 (8), 774-786, 2017 | 365 | 2017 |
| IDH mutant gliomas escape natural killer cell immune surveillance by downregulation of NKG2D ligand expression X Zhang, A Rao, P Sette, C Deibert, A Pomerantz, WJ Kim, G Kohanbash, ... Neuro-oncology 18 (10), 1402-1412, 2016 | 157 | 2016 |
| Combined vaccine+ axitinib therapy yields superior antitumor efficacy in a murine melanoma model A Bose, DB Lowe, A Rao, WJ Storkus Melanoma research 22 (3), 236-243, 2012 | 70 | 2012 |
| Molecular profiles and immunomodulatory activities of glioblastoma-derived exosomes JH Azambuja, N Ludwig, S Yerneni, A Rao, E Braganhol, TL Whiteside Neuro-oncology advances 2 (1), vdaa056, 2020 | 63 | 2020 |
| Combination therapy with HSP90 inhibitor 17-DMAG reconditions the tumor microenvironment to improve recruitment of therapeutic T cells A Rao, JL Taylor, N Chi-Sabins, M Kawabe, WE Gooding, WJ Storkus Cancer research 72 (13), 3196-3206, 2012 | 57 | 2012 |
| Elevated Na/H exchanger 1 (SLC9A1) emerges as a marker for tumorigenesis and prognosis in gliomas X Guan, L Luo, G Begum, G Kohanbash, Q Song, A Rao, N Amankulor, ... Journal of Experimental & Clinical Cancer Research 37, 1-16, 2018 | 52 | 2018 |
| Characterization of systemic immunosuppression by IDH mutant glioma small extracellular vesicles N Ludwig, A Rao, P Sandlesh, SS Yerneni, AD Swain, KM Bullock, ... Neuro-oncology 24 (2), 197-209, 2022 | 27 | 2022 |
| Adenosine receptors regulate exosome production N Ludwig, JH Azambuja, A Rao, DG Gillespie, EK Jackson, TL Whiteside Purinergic Signalling 16, 231-240, 2020 | 16 | 2020 |
| Autophagy inhibition is the next step in the treatment of glioblastoma patients following the Stupp era X Zhang, CP Deibert, WJ Kim, E Jaman, AV Rao, MT Lotze, ... Cancer gene therapy 28 (9), 971-983, 2021 | 9 | 2021 |
| In vivo efficacy of decitabine as a natural killer cell–mediated immunotherapy against isocitrate dehydrogenase mutant gliomas X Zhang, WJ Kim, AV Rao, E Jaman, CP Deibert, P Sandlesh, K Krueger, ... Neurosurgical Focus 52 (2), E3, 2022 | 6 | 2022 |
| Shock block for improved immunotherapy A Rao, DB Lowe, WJ Storkus Oncoimmunology 1 (8), 1427-1429, 2012 | 6 | 2012 |
| Role of natural killer cells in isocitrate dehydrogenase 1/2 mutant glioma pathogenesis and emerging therapies X Zhang, A Safonova, A Rao, N Amankulor Glioma 2 (3), 133-138, 2019 | 2 | 2019 |
| Combination immunotherapy of melanoma by inhibiting HSP90 and targeting its client proteins.(TUM7P. 934) S Raveendran, A Rao, W Storkus The Journal of Immunology 192 (1_Supplement), 203.16-203.16, 2014 | 2 | 2014 |
| Integration of HSP90 inhibitors in combinational immunotherapy targeting receptor tyrosine kinases (RTKs) in cancer (131.45) A Rao, M Kawabe, W Storkus The Journal of Immunology 184 (1_Supplement), 131.45-131.45, 2010 | 1 | 2010 |
| All-trans retinoic acid induces durable tumor immunity in IDH-mutant gliomas by rescuing transcriptional repression of the CRBP1-retinoic acid axis A Rao, X Zhang, A Cillo, JH Sussman, P Sandlesh, AC Tarbay, ... bioRxiv, 2024.04. 09.588752, 2024 | | 2024 |
| ALL-TRANS RETINOIC ACID INDUCES DURABLE TUMOR IMMUNITY IN IDH MUTANT GLIOMAS AND CIRCUMVENTS REPRESSION OF CRBP1-RETINOIC ACID AXIS X Zhang, A Rao, A Cillo, A Mallela, K Krueger, T Bruno, N Amankulor NEURO-ONCOLOGY 24, 287-287, 2022 | | 2022 |
| Autophagy inhibition is the next step in the treatment of glioblastoma patients following the Stupp era NMA Xiaoran Zhang, Christopher P Deibert, Wi-Jin Kim, Emade Jaman, Aparna V ... Cancer Gene Therapy 28 (9), 971-983, 2021 | | 2021 |
| Retinoid compositions and methods of increasing immune cell-mediated killing of IDH mutant cancer cells N Amankulor, A Rao US Patent 10,821,091, 2020 | | 2020 |
| Neuro-Oncology Advances JH Azambuja, N Ludwig, S Yerneni, A Rao, E Braganhol, TL Whiteside | | 2020 |
| Isolation and characterization of exosomes from IDH mutant gliomas. N Ludwig, A Rao, SS Yerneni, N Amankulor, T Whiteside Journal of Clinical Oncology 37 (8_suppl), 152-152, 2019 | | 2019 |
Christopher P DeibertUniversity of Pittsburgh在 upmc.edu 的电子邮件经过验证
Christopher P DeibertUniversity of Pittsburgh在 upmc.edu 的电子邮件经过验证